| 8.07 -0.005 (-0.06%) | 07-22 10:24 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.8 | 1-year : | 11.82 |
| Resists | First : | 9.25 | Second : | 10.11 |
| Pivot price | 8.82  |
|||
| Supports | First : | 7.84 | Second : | 6.52 |
| MAs | MA(5) : | 8.09 |
MA(20) : | 8.87 |
| MA(100) : | 9.12 |
MA(250) : | 8.43 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 7.4 |
D(3) : | 6.1 |
| RSI | RSI(14): 36.6 |
|||
| 52-week | High : | 11.97 | Low : | 6.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NVAX ] has closed above bottom band by 20.6%. Bollinger Bands are 13.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.13 - 8.18 | 8.18 - 8.23 |
| Low: | 7.77 - 7.82 | 7.82 - 7.88 |
| Close: | 7.99 - 8.07 | 8.07 - 8.15 |
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine, which is in Phase II clinical trials for adults aged 60 and older, and in Phase I for pediatric use. The company holds a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of its COVID-19 vaccine candidate, NVX-CoV2373. Established in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland.
Tue, 21 Jul 2026
Novavax, Inc. (NVAX) Stock Analysis: Potential Upside of 79.10% Amidst Challenging Financial Metrics - DirectorsTalk Interviews
Mon, 20 Jul 2026
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Wed, 15 Jul 2026
NVAX News | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Tue, 07 Jul 2026
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Wed, 24 Jun 2026
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Tue, 23 Jun 2026
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 164 (M) |
| Shares Float | 141 (M) |
| Held by Insiders | 5 (%) |
| Held by Institutions | 69.4 (%) |
| Shares Short | 45,810 (K) |
| Shares Short P.Month | 45,970 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.88 |
| Profit Margin | -14.8 % |
| Operating Margin | -7.2 % |
| Return on Assets (ttm) | 1.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -79.1 % |
| Gross Profit (p.s.) | 0.99 |
| Sales Per Share | 3.62 |
| EBITDA (p.s.) | 0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -92 (M) |
| Levered Free Cash Flow | 59 (M) |
| PE Ratio | -14.45 |
| PEG Ratio | 1.3 |
| Price to Book value | -9.2 |
| Price to Sales | 2.23 |
| Price to Cash Flow | -14.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|